B cell--intrinsic TLR9 expression is protective in murine lupus {#sec1}
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**Tilstra *et al.*** (*J Clin Invest*. 2020;130:3172--3187.)

Toll-like receptors (TLRs) are pathogen recognition receptors, and their engagement activates proinflammatory transcription factors like nuclear factor kappa B (NF-κB) and interferon regulators. A large body of evidence supports a role for TLRs in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). For example, TLR9 senses double-stranded DNA (dsDNA) and drives anti-dsDNA autoantibody production, whereas TLR7 drives anti-RNA autoantibodies. Unexpectedly, *Tlr9*-deficient lupus-prone mice have worse SLE and LN despite the absence of anti-dsDNA and anti-nucleosome autoantibodies. This paradoxical effect occurs, even though TLR9 and TLR7 have nearly identical downstream signaling pathways.

Tilstra and colleagues postulated that the apparent protective effect of TLR9 in lupus may be due to cell type--specific expression of the receptor, so they examined the consequences of deleting TLR9 expression in single leukocyte cell types on SLE in the MRL/*lpr* lupus model. They created cell-specific conditional knockout mice. Deletion of TLR9 on B cells resulted in increased proteinuria, glomerular inflammation, and interstitial inflammation. Antichromatin antibodies were absent, but there was an increase in staining for anti-RNA specificities. There were fewer CD19+ B cells as a total proportion of splenocytes but a relative increase in double-negative T cells. Unlike mice globally deficient in TLR9, the B cell--deficient mice did not have worse dermatitis or significant lymphadenopathy. The exacerbation of LN was not recapitulated in mice with TLR-9-deficient dendritic cells (conventional and plasmacytoid), neutrophils, and macrophages, although complete knockout of TLR9 in macrophages was difficult to achieve. When the investigators overexpressed *Tlr9* in B cells, proteinuria and glomerular inflammation were attenuated, but there was no effect on interstitial inflammation.

These provocative data demonstrate that TLR9 expression by B cells may be protective for LN. Moreover, LN can develop in the absence of antichromatin autoantibodies, one of the hallmarks of lupus and LN. Interestingly, some IgM anti-dsDNA antibodies have been shown to be protective. Recent studies suggest that B cells from patients with SLE are hyporesponsive to TLR9 stimulation, and this may result in a loss of a protective mechanism. Therapeutically, systemic administration of a TLR9 agonist has been used in cancer treatment. Augmenting TLR9 responses in B cells may have a place in the treatment of SLE, especially in patients with LN. These data also raise concerns regarding global B cell depletion as a treatment for LN and may account for some patients who do not respond to anti-CD20 therapies.

**---Brad H. Rovin**

Management of coronary disease in patients with advanced kidney disease {#sec2}
=======================================================================

**Bangalore *et al.*** (*N Engl J Med*. 2020;382:1608--1618.)

Cardiovascular disease is significantly increased in patients with chronic kidney disease (CKD) and is the leading cause of mortality. Coronary angiography and percutaneous intervention (PCI) are associated with kidney injury in patients with CKD, and the treatment benefits from revascularization have not been studied in large populations.

The authors report on the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches--Chronic Kidney Disease (ISCHEMIA-CKD) to test whether there is incremental benefit of an initial invasive strategy added to medical therapy in patients with stable coronary disease and advanced chronic kidney disease. Seven hundred seventy-seven adult patients with at least moderate ischemia on a stress test were randomized in 30 countries. Fifty-seven percent were diabetic and 53% were on dialysis. The median glomerular filtration rate (GFR) in the non-dialyzed patients was 23 ml/min per 1.73 m^2^. In the invasive (INV) group, 85% underwent coronary angiography and 50% revascularization. In the conservative (CONS) group, 32% underwent coronary angiography and 20% revascularization.

The primary outcome was a composite of death or nonfatal myocardial infarction. A key secondary outcome was a composite of death, nonfatal myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. Patients were followed up for a median 2.2 years (interquartile range, 1.6--3.0). The primary outcome event was not significantly different; 123 patients in the INV group versus 129 patients in the CONS group ([Figure 1](#fig1){ref-type="fig"} ). Moreover, estimated 3-year cumulative incidence of the primary outcome was not significantly different either; 36% in the INS group versus 37% in the CONS group. The key secondary outcome was also not significantly different; 132 patients in the INV group versus 138 patients in the CONS group.Figure 1**Results of the time-to-event analysis for the primary outcome (a composite of death or nonfatal myocardial infarction) (a) and a key secondary outcome (a composite of death, nonfatal myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest) (b) among patients in the invasive-strategy group and the conservative-strategy group.** From *New England Journal of Medicine*, Bangalore S, Maron DJ, O'Brien SM, et al. Management of coronary disease in patients with advanced kidney disease, volume 382, pages 1608--1618. Copyright © 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

There were some caveats to the trial findings. Patients with heart failure, recent acute coronary syndromes, or ejection fraction of less than 35% were excluded from the trial, limiting generalizability. Moreover, the event rates were lower than projected, and the low incidence of revascularization was also lower in the INV group, which might affect power of the trial. However, Bayesian analysis showed that the probability that assignment to the invasive strategy reduced or increased the risk of the primary outcome by more than 10% was low.

In conclusion, in patients with stage 4/5 CKD or end-stage kidney disease (ESKD), and stable coronary disease with moderate or severe ischemia on stress test, an invasive strategy did not reduced the risk of death or nonfatal myocardial infarction.

**---Jai Radhakrishnan**

Renin-angiotensin-aldosterone system blockers and the risk of COVID-19 {#sec3}
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**Mancia *et al.*** (Renin--angiotensin--aldosterone system blockers and the risk of Covid-19. *N Engl J Med.* 2020;382:2431--2440.)

**Reynolds *et al.*** (Renin--angiotensin--aldosterone system inhibitors and risk of Covid-19. *N Engl J Med*. 2020;382:2441--2448.)

**de Abajo *et al.*** (Use of renin--angiotensin--aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. *The Lancet.* 2020;395:1705--1714.)

There is evidence from animal studies to suggest severe acute respiratory syndrome coronavirus (SARS-CoV-2) may infect the host cell by interacting with the membrane-bound angiotensin-converting enzyme 2 (ACE2) on the respiratory epithelium. Therefore, ACE inhibitors and angiotensin-receptor blockers (ARBs) may upregulate the ACE2 expression and enhance the entry of the SARS-CoV-2 virus into the target cell. Against this background, some have speculated ACE inhibitors and ARBs are potentially harmful in patients with coronavirus disease 2019 (COVID-19). In view of the current pandemic, clinicians are particularly concerned of the potential harms these anti-hypertensives may incur in high-risk individuals such as those with diabetes and kidney disease. Three observational studies, now published in the *New England Journal of Medicine* and *The Lancet*, have examined the association between ARBs and ACE inhibitors and this risk of COVID-19.

In the study by Mancia *et al.*, 6272 patients with confirmed COVID-19 and 30,759 controls were included in a population-based case-control study conducted in the Lombardy region of Italy. In this matched analysis, the authors found no increased risk of COVID-19 infection between the exposed (ARBs and/or ACE inhibitors) and unexposed groups after adjusting for the effect of age, sex, and other comorbidities. Furthermore, ARBs and ACE inhibitors were not associated with an increase of severe or fatal infections related to COVID-19. Reynolds *et al.* conducted a matched cohort analysis using data from the New York University Langone Health Electronic health records. The authors used Bayesian and frequentist approaches to assess the risk of COVID-19 between patients treated with and without ARBs and ACE inhibitors. To account for confounding and indication biases, a propensity score matched model was built and no substantive differences in the risk of COVID-19 between the treatment and no treatment groups were observed. In the case-population study by de Abajo *et al.*, which included hospital admission data from 7 hospitals in Madrid (1139 cases and 11,390 controls), no increased risk of COVID-19 was found either for ACE inhibitors or ARBs. None of these studies reported any interactive effects with CKD stage, age, and sex.

These findings are reassuring and consistent with the international professional bodies and guidelines indicating ACE inhibitors and ARBs should not be modified to manage COVID-19 risk or infection. However, readers must be cognizant of the potential limitations inherent to observational studies, including selection, information, indication, confounding, and measurement biases, and should interpret the data with caution. Ultimately, well-powered and well-conducted randomized controlled trials are needed to answer the question with certainty.

**---Germaine Wong**

Evidence of tissue repair in human donor pancreas after prolonged duration of stay in intensive care mediated by M2 macrophages? {#sec4}
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**Smeets *et al.*** (Evidence of tissue repair in human donor pancreas after prolonged duration of stay in intensive care. *Diabetes.* 2020;69:401--412.)

It is generally regarded that pancreatic beta cells fail to replicate after neonatal or early fetal life. In adult humans, this lack of replicative capacity limits the ability of the pancreas to respond to stresses such as development of autoimmune type 1 diabetes or the loss of functional beta cell mass in type 2 diabetes. Alternatively, activated M2 macrophages have been shown to play an important role in tissue repair, regeneration, and angiogenesis, and in experimental animal models may play a role in beta cell development. In this study of organ donors by Smeets *et al.*, the number of CD68+ CD206+ M2 pancreatic macrophages dramatically increased during prolonged stay in the intensive care unit (ICU). Using the Ki67 marker, a significant increase in replicating pancreatic cells was noted within 6 days of ICU stay, with an increase to 9-fold expansion by day 12 of the ICU stay. A significant increase in pancreatic vascular density was noted in donors with increasing length of stay ([Figure 2](#fig2){ref-type="fig"} a), and M2 macrophage number was correlated with pancreatic beta cell regeneration ([Figure 2](#fig2){ref-type="fig"}b). Taken together, these observations add to the evidence of potential M2 macrophages--induced tissue repair in humans, with the tantalizing prospect of repair of insulin-secreting tissue through the effect of M2 recruitment into diseased organs. Furthermore, the changes in tissue vascularization indirectly suggest a role for M2 macrophages as a novel cell therapy to promote regeneration and revascularization in humans. These studies have interesting implications for the role of M2 macrophages as potential adjunctive therapy for organ and tissue regeneration, as well as implications for beta cell recovery in transplanted whole pancreas from longer-stay ICU donors.Figure 2**(a) Double-positive CD68+CD206+ M2 macrophages in the pancreas of organ donors at day 0, day 6, and day 12 of ICU stay.** (**b**) Correlation between Ki67+/insulin-positive cells and CD68+CD206+ M2 macrophages in donor pancreases. Adapted with permission from Smeets S, Stangé G, Leuckx G, et al. Evidence of tissue repair in human donor pancreas after prolonged duration of stay in intensive care. *Diabetes.* 2020;69:401--412. Copyright © 2019 American Diabetes Association. To optimize viewing of this image, please see the online version of this article at [www.kidney-international.org](http://www.kidney-international.org){#intref0020}.

**---P. Toby Coates**
